Genomic Disorders 2013: From 60 years of DNA to human genomes in the clinic

The 7th Wellcome Trust Genomic Disorders conference will present an exciting blend of genomic science and clinical medicine. This meeting aims to bring together scientists and clinicians interested in genomic variation in humans and the mechanisms by which it exerts its phenotypic effects.

Genomic Disorders 2013 will discuss the latest findings relating to the genomic basis of rare disorders as these can provide such powerful insights into human biology. Genome-wide analyses, including array Comparative Genomic Hybridization (aCGH) and Whole Exome Sequencing (WES), are proving to be of great value in discovering the genetic basis of rare disorders and illustrate the heuristic power of humans as a model organism. A particular focus of this meeting will be on bioinformatics approaches used to interpret genomic variants and on therapeutic targets for rare genetic diseases.
Scientific sessions will include:
Natural variation
Developmental genetics
Animal models of rare disorders
Interpretation of genomic variants
Therapeutics

+ show speakers and program
Conference Summary

Wednesday 10 April 2013
15.00-17.00 Registration
17.00-18.30 Session 1: DNA Celebrating 60 years (1953-2013)
18.30-19.30 Poster session I (odd numbers) and pre-dinner drinks
19.30 Dinner

Thursday 11 April 2013
09.00-10.30 Session 2: Natural variation
10.30-11.00 Morning Coffee
11.00-13.00 Session 3: Epigenomics
13.00-14.00 Lunch
14.00-16.00 Session 4: Developmental genetics
16.00-16.30 Afternoon Tea
16.30-18:00 Session 5: Interpretation of genomic variants
18.00-19.30 Poster session II (even numbers) and pre-dinner drinks
19.30 Conference Dinner

Friday 12 April 2013
09.00-10.30 Session 6: Mutational processes
10.30-11.00 Morning Coffee
11.00-13.00 Session 7: Genetic risk – perception of risk and impact on behavior
13.00-14.00 Lunch
14.00-15.30 Session 8: Animal Models
15.30-16.00 Afternoon Tea
16.00-17.30 Session 9: Therapeutics
17:30 conference closes

Invited speakers:
Gonçalo Abecasis University of Michigan, USA
Les Biesecker NIH, USA
Ewan Birney EMBL-EBI, UK
Sydney Brenner Howard Hughes Medical Institute, USA
Johan den Dunnen Leiden University Medical Center, The Netherlands
Santhosh Girirajan Pennsylvania State University, USA
Robert C. Green Brigham and Women's Hospital and Harvard Medical School, USA
Tamar R. Grossman ISIS Pharmaceuticals, USA
Monica Justice Baylor College of Medicine, USA
Nico Katsanis Duke University, USA
Ben Lehner, Centre for Genomic Regulation, Spain
Jennifer Lentz LSU Health Sciences Center, USA
John Mattick Garvan Institute of Medical Research, Australia
Serena Nik-Zainal Wellcome Trust Sanger Institute, UK
Wolf Reik Babraham Institute, UK
Renata Salecl University of Ljubljana, Slovenia
Annette Schenck Radboud University Nijmegen Medical Centre, The Netherlands
Nicole Soranzo Wellcome Trust Sanger Institute, UK
Chris Tyler-Smith Wellcome Trust Sanger Institute, UK
James Watson Cold Spring Harbor Laboratories, USA
Brunhilde Wirth University of Cologne, Germany

10 Apr - 12 Apr 2013
Cambridge
United Kingdom
meeting website